2024年12月25日 · FGF19 (Fibroblast Growth Factor 19) is a Protein Coding gene. Diseases associated with FGF19 include Alagille Syndrome 1 and Functional Diarrhea . Among its related pathways are Apoptotic Pathways in Synovial Fibroblasts and GPCR Pathway .

Recent structural and biochemical studies have begun to shed light onto the molecular basis for the klotho-dependent endocrine mode of action of the FGF 19 subfamily.

2011年3月18日 · Fibroblast growth factor 19 (FGF19) is a hormone-like protein that regulates carbohydrate, lipid and bile acid metabolism. At supra-physiological doses, FGF19 also increases hepatocyte proliferation and induces hepatocellular carcinogenesis in mice.

Representatives of the FGF19 subclass, including FGF19, FGF21, and FGF23, act via FGFR receptors. The proteins of FGF19 subfamily influence the enterohepatic circulation of bile, participate in glucose and lipid metabolism regulation, and maintenance of phosphorus and vitamin D3 homeostasis.

2019年6月14日 · Fibroblast growth factor (FGF) 15 in mice and its human orthologue FGF19 (together denoted FGF15/19) are gut hormones that control homeostasis of bile acids and glucose during the transition...

Fibroblast growth factor 19 (FGF19) is a member of the hormone-like FGF family and has activity as an ileum-derived postprandial hormone [15, 16]. It shares high binding affinity with β-Klotho and together with the FGF receptor 4 (FGFR4), is predominantly targeted to the liver [17].

Fibroblast growth factor 19 (FGF19) is a gut hormone with pleiotropic effects.77 It is secreted by the small intestine in response to feeding. FGF19 has insulinlike actions, such as promoting glucose uptake in adipocytes, synthesizing hepatic glycogen, and inhibiting gluconeogenesis.

Fibroblast growth factor 19 (FGF19) is an ileum-derived postprandial enterokine that regulates hepatic protein and glucose metabolism. Both FGF19 and insulin promote protein and glycogen synthesis and inhibit gluconeogenesis in liver.

Fibroblast growth factor 19 alleviates palmitic acid-induced mitochondrial dysfunction and oxidative stress via the AMPK/PGC-1alpha pathway in skeletal muscle. Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104.

The FGF19 subclass includes growth factors circulating with the blood referred to as endocrine FGF. Representatives of the FGF19 subclass, including FGF19, FGF21, and FGF23, act via FGFR receptors.